Skip to main content
Membership NewsMembership News Archive

Steering diagnostic innovation to address the unmet needs in managing lung infections in people with cystic fibrosis

By June 4, 2024No Comments

On June 5th 2024, the Cystic Fibrosis (CF) Antimicrobial Resistance (AMR) Syndicate launched their diagnostic target product profiles (TPPs) detailing key characteristics of new tests needed to detect and manage lung infections and exacerbations in CF.

The CF AMR Syndicate together with the Newcastle NIHR HealthTech Research Centre (HRC), have undertaken extensive engagement with a broad range of experts across the CF AMR community, including people affected by CF and their clinical teams, as well as academic and industrial researchers to capture the unmet needs and define the key characteristics for the TPPs.

The acceptance of a diagnostic test among people with CF is paramount to its successful use. These TPPs provide a consensus-led ‘blueprint’ for innovators, to guide development of tests that are compatible with the needs and priorities of people with CF.

The CF AMR Syndicate is a collaboration between the Medicines Discovery Catapult, Cystic Fibrosis Trust and LifeArc. It brings together leading experts in CF/AMR from industry, academia and people living with CF to accelerate the discovery and development of new antimicrobials and diagnostics for CF related lung infections.

Visit their website to get your copy of the TPPs, join the CF AMR network and work with them to advance new tests.

Ben Kemp